Grants and Projects
Through collaboration and innovation, we spearhead critical research of schizophrenia and other psychotic disorders. See below for our team’s current grants and projects.
René S. Kahn, MD, PhD
- European Long-acting Antipsychotics in Schizophrenia Trial (EULAST) (2014-002765-30)
- Omega Fatty Acids Trial in Ultra High Risk Subjects (PURPOSE) (2015-003503-39)
- A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder (ALK3831-A307)
- A Phase 3 Study to Assess the Long-Term Safety, Tolerability and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder (ALK3831-A308)
- Prevention of Symptoms and Psychosis through Education and Cognitive Therapy (PrOSPECT)
- Longitudinal Neuroimaging and Neurocognitive Assessment of Risk and Protective Factors Across the Schizophrenia Spectrum (R01MH121411)
- Psychosis Risk Evaluation, Data Integration and Computational Technologies (PREDICT): Data Processing, Analysis, and Coordination Center (1U24MH124629-01)
Alexander Charney, MD, PhD
- A Multiscale Investigation of The Living Human Brain (5R01AG069976-02)
- Leveraging EHR-Linked Biobanks for Deep Phenotyping, Polygenic Risk Score Modeling, and Outcomes Analysis in Psychiatric Disorders (5R01MH121923-03)
- Psychiatric Genomics Consortium: Finding Actionable Variation (5U01MH109536-05)
Dolores Malaspina, MD, MS, MSPH
Cheryl Corcoran, MD
- Schizophrenia Spectrum Biomarkers Consortium
- Thought Disorder and Social Cognition in Clinical Risk States for Schizophrenia (R01MH107558)
- Using the RDoC Approach to Understand Thought Disorder: A Linguistic Corpus-Based Approach (1R01MH115332)
- Psychosis-risk Outcomes Network (ProNET) (U01MH124639)